Drug Trial Radar · NCT01360554
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: May 24, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
878
Actual
Start
Jun 16, 2011
Primary completion
Sep 30, 2013
Study completion Sep 14, 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multinational, multicenter, randomized,double-blinded, Phase 3 study comparing the efficacy and safety of treatment with PF-00299804 to treatment with erlotinib in patients with advanced non-small cell lung cancer, previously treated with at least one prior regimen. Analyses of primary objective (Progression Free Survival) will be done in two co-primary populations as defined in the protocol.
Conditions
- Non-Small Cell Lung Cancer
Interventions
Dacomitinib (PF-00299804)Drug
Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
Active Comparator (erlotinib)Drug
Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
Placebo erlotinibDrug
placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
Placebo PF00299804Drug
placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) Per Independent Radiologic Review.Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.
- Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, participants were followed up until progressive disease regardless of start of subsequent cancer therapy.
Locations
224 sites in 23 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Northwest Alabama Cancer Center
Florence, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
University of South Alabama Medical Center
Mobile, Alabama
Northwest Alabama Cancer Center
Muscle Shoals, Alabama
Ironwood physicians P C dba Ironwood Cancer & Research Centers
Chandler, Arizona
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Chandler, Arizona
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Gilbert, Arizona
Desert Oncology Associates dba Ironwood Cancer and Research Centers
Mesa, Arizona
Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers
Mesa, Arizona
Highlands Oncology Group PA
Fayetteville, Arkansas
Highlands Oncology Group, PA
Rogers, Arkansas
Central Hematology Oncology Medical Group Inc.
Alhambra, California
UCLA Hematology Oncology-Alhambra
Alhambra, California
City of Hope
Duarte, California
St. Jude Heritage Healthcare
Fullerton, California
Drug Management Only
Los Angeles, California
Drug Managerrent Only:
Los Angeles, California
UCLA West Medical Pharmacy
Los Angeles, California
Administrative Address: UCLA Hematology Oncology-Clinical Research Unit (CRU)
Los Angeles, California
Drug Shipment Address: Ronald Reagan UCLA Medical Center, Drug Information Center
Los Angeles, California
Regulatory Management Only:
Los Angeles, California
Regulatory Management:
Los Angeles, California
Ronald Reagan UCLA Medical Center
Los Angeles, California
TORI Central Administration
Los Angeles, California
Westwood Bowyer Clinic, Peter Morton Medical Building
Los Angeles, California
UCLA/Pasadena Healthcare Hematology-Oncology
Pasadena, California
Central Hematology Oncology Medical Group, Inc.
Pasadena, California
Cancer Care Associates Medical Group Inc.
Redondo Beach, California
Central Coast Medical Oncology Corporation
Santa Maria, California
UCLA Hematology Oncology-Parkside
Santa Monica, California
UCLA Hematology Oncology-Santa Monica
Santa Monica, California
UCLA Santa Monica Medical Center & Orthopedic Hospital
Santa Monica, California
City of Hope South Pasadena Cancer Center
South Pasadena, California
UCLA/Santa Clarita Valley Cancer Center
Valencia, California
UCLA Cancer Center
Westlake Village, California
Norwalk Hospital
Norwalk, Connecticut
Florida Hospital
Orlando, Florida
Showing 40 of 224 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.